📚 Part of the OBX-319 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.

---

Module 3.2.P — Drug Product (OBX-319)

Document ID: M3-P
Version: 1.0
Change History: 1.0 — Initial issue.
Standard(s): ICH Q5A-Q5E, Q6B, Q1A(R2), Q11, M4Q

3.2.P Drug Product — OBX-319

OBX-319 is a humanized, bispecific IgG1 monoclonal antibody that engages CD19 and CD20 on B lymphocytes to produce near-complete peripheral B-cell depletion in moderate-to-severe active Systemic Lupus Erythematosus (SLE). The active is expressed in a Chinese hamster ovary (CHO) cell line and purified by Protein A capture followed by polishing chromatography; the drug substance is described in Module 3.2.S. This module describes the finished drug product presented for subcutaneous administration in the pivotal study OBX319-301 (Virtual Biopharma Inc.). Because the molecule is a bispecific antibody with two distinct antigen-binding specificities on a single IgG1 scaffold, product-quality control is designed around correct chain pairing, dual functional activity, and the aggregation/charge-heterogeneity profile characteristic of high-concentration antibody products, consistent with ICH Q5A(R2), Q5C, Q5E, and Q6B.

3.2.P.1 Description and Composition

The drug product is a sterile, preservative-free aqueous solution for subcutaneous injection presented in a single-use prefilled syringe and in a single-use autoinjector built on the same primary container. It is formulated to support subcutaneous administration of OBX-319 across the dose levels evaluated in OBX319-301 (OBX-319 High, OBX-319 Low, Placebo). The active substance is a full-length bispecific humanized IgG1 (anti-CD19 x anti-CD20) of approximately 150 kDa bearing an engineered CH3 interface that drives correct heavy-chain heterodimerization and a common/orthogonal light-chain design that suppresses light-chain mispairing.

A single formulation and fill concentration are used for both active dose levels; the High and Low doses are delivered by the number of prefilled-syringe/autoinjector units administered per dosing visit rather than by a difference in concentration. The Placebo presentation is composition-matched vehicle without active substance in the identical container-closure and device, preserving the double blind.

Nominal unit composition (per mL) is summarized below; excipients are compendial (Ph. Eur./USP-NF) and are present at conventional levels for a high-concentration subcutaneous antibody.

Component	Function	Nominal amount (per mL)
OBX-319 (anti-CD19 x anti-CD20 bispecific IgG1)	Active substance	150 mg
L-Histidine / L-histidine hydrochloride	Buffer (target pH ~5.8)	~20 mM
Sucrose	Stabilizer / tonicity	~250 mM
L-Arginine hydrochloride	Viscosity reduction / colloidal stabilizer	~50 mM
Polysorbate 80	Surfactant (anti-aggregation, interface protection)	~0.4 mg
Water for injection	Solvent	q.s. to 1 mL

The solution is isotonic, formulated near pH 5.8 to minimize deamidation and aggregation, and contains no antimicrobial preservative, consistent with single-use administration.

3.2.P.2 Pharmaceutical Development

Formulation and process development established a robust, stable presentation; critical quality attributes track those of the drug substance. Development was framed by a Quality Target Product Profile (QTPP): a subcutaneously deliverable, high-concentration solution that is stable at 2-8 C, isotonic and low-viscosity enough for autoinjector delivery, and that maintains correct bispecific chain pairing and dual target binding throughout shelf life.

Critical quality attributes (CQAs) were identified through risk assessment (ICH Q8/Q9/Q6B) and prioritized by potential impact on efficacy, immunogenicity, and safety:

• Correct assembly / chain pairing — content of the intended heterodimeric bispecific species relative to homodimer, half-antibody, and light-chain-mispaired variants; monitored because mispaired species can lose one specificity and alter potency or immunogenicity.
• Dual potency — retention of both anti-CD19 and anti-CD20 binding and the resulting B-cell-depleting function.
• Aggregation / high-molecular-weight species — a key immunogenicity and efficacy risk at 150 mg/mL.
• Charge variants — acidic/basic species arising from deamidation, isomerization, C-terminal lysine, and glycation.
• Fragmentation — clipping in hinge/CH regions.
• N-glycosylation and Fc-effector-relevant attributes — including afucosylation, high-mannose, and galactosylation, which can modulate FcγR-mediated activity contributing to B-cell depletion.
• Subcutaneous-delivery attributes — viscosity, injection/glide force, extractable volume, and subvisible particulates.

High-concentration formulation development addressed the principal liabilities of a 150 mg/mL bispecific IgG1: elevated viscosity, opalescence, reversible self-association, and interface/agitation-induced aggregation. Buffer, sugar, amino-acid, and surfactant selection was optimized by design-of-experiments screening against forced-degradation and real-time stability endpoints; L-arginine and the histidine/sucrose system were selected to control viscosity and colloidal stability while keeping pH in a range that limits chemical degradation. Polysorbate 80 level was set to protect against interfacial stress during fill, shipping agitation, and device actuation, balanced against polysorbate degradation and particle formation.

Device and delivery development qualified injection force, glide force, and dose accuracy across the labeled 2-8 C storage condition and after ambient equilibration, and confirmed that the formulation viscosity supports reproducible delivery through the staked needle in both the prefilled syringe and autoinjector configurations. Comparability across development stages and the pivotal-lot process was established per ICH Q5E, including bridging of analytical methods and confirmation that the bispecific assembly and dual-potency profile were maintained.

3.2.P.3 Manufacture

The product is manufactured by compounding, sterile filtration, aseptic fill-finish, and device assembly under GMP, with validated in-process controls. The finished-product process comprises: controlled thaw and pooling of drug substance; compounding/formulation to the target protein concentration and excipient composition; bioburden-reduction filtration; redundant sterilizing-grade (0.22 µm) filtration; aseptic filling into pre-sterilized Type I glass syringe barrels; stoppering and, where applicable, plunger-rod and autoinjector assembly; and 100% inspection followed by labeling and packaging.

The process is operated within a validated design space with defined critical process parameters and in-process controls, including protein concentration and pH at compounding, pre- and post-filtration bioburden, filter integrity testing (pre- and post-use), fill-weight/extractable-volume checks, and stopper placement. Solution hold times (pre-filtration, post-filtration, and pre-fill) are validated for chemical, physical, and microbiological stability, and shear/agitation exposure during compounding and filling is controlled to protect the aggregation and subvisible-particle profile of the high-concentration bispecific.

Aseptic processing is qualified by media fills, and the sterilizing filtration step is validated for bacterial retention, extractables/leachables, and non-adsorption of active substance and polysorbate. Because sterility is achieved by filtration and aseptic fill rather than terminal sterilization, environmental monitoring, sterilization of components, and container-closure integrity assurance are integral to the control strategy. Process performance qualification demonstrated reproducible delivery of product meeting the release specification, and adventitious-agent control for the upstream biological source is addressed in Module 3.2.A in accordance with ICH Q5A(R2).

3.2.P.5 Control of Drug Product

The release/shelf-life specification:

Attribute	Analytical procedure	Acceptance criterion
Appearance	Visual	Clear, colourless to slightly yellow solution
Protein concentration	UV A280	150 mg/mL +/- 10%
Purity (monomer)	SE-HPLC	Monomer >= 95%
Potency	Cell-based reporter	80-125% of reference
Sub-visible particles	Light obscuration	Meets USP <788>
Sterility	USP <71>	Sterile
Container-closure integrity	Physical method	Pass

The specification above is supported by additional identity, purity/impurity, and functional controls appropriate to a bispecific antibody, applied at release and on stability as part of the total control strategy (ICH Q6B):

• Identity — confirmation of the bispecific molecule by an orthogonal approach establishing both binding specificities (for example, dual-binding ligand assay and/or peptide-map/intact-mass identity), distinguishing OBX-319 from monospecific or mispaired species.
• Assembly and size heterogeneity — non-reducing and reducing CE-SDS to quantify intact bispecific content, half-antibody/fragments, and low-molecular-weight species; SE-HPLC additionally reports aggregate (high-molecular-weight) content alongside the monomer criterion above.
• Charge heterogeneity — imaged capillary isoelectric focusing (iCIEF) or ion-exchange chromatography to monitor acidic/basic variants (deamidation, isomerization, C-terminal lysine).
• Potency — the cell-based reporter measures the functional, B-cell-directed activity that depends on engagement of both CD19 and CD20; where warranted, dual-antigen binding is additionally confirmed to ensure both arms remain active (a bispecific molecule that has lost one specificity must not pass on a single-arm readout).
• Safety attributes — bacterial endotoxin (USP <85>) and bioburden, in addition to the sterility control tabulated above.
• Delivered-dose and device attributes — extractable volume and, for the autoinjector, functional/dose-delivery performance.

All analytical procedures are validated per ICH Q2(R1)/Q2(R2) and, where compendial, verified for the matrix. Acceptance criteria are justified by clinical qualification (batches representative of those used in OBX319-301), manufacturing capability, and stability behavior. A qualified two-tier reference standard (primary and working) traceable to clinical material anchors the potency, charge, and size methods; its establishment and requalification are described in the reference-standard documentation. The specification, including the tabulated criteria for concentration (150 mg/mL +/- 10%), monomer purity (>= 95%), and potency (80-125% of reference), is consistent with maintenance of correct bispecific assembly and dual function across shelf life.

3.2.P.7 Container-Closure System

Type I glass prefilled syringe with a coated elastomeric stopper, assembled into an autoinjector, qualified for extractables/leachables and container-closure integrity. The primary container is a pre-sterilized Type I borosilicate glass syringe barrel with a staked stainless-steel needle, a rigid needle shield, and a fluoropolymer-coated (for example, ETFE) elastomeric plunger stopper selected to minimize leachables and protein/surfactant adsorption. The same primary container is used for the prefilled-syringe and autoinjector presentations and for the composition-matched Placebo, preserving the study blind.

Suitability was demonstrated per USP <1660>/<661> and ICH Q3D/Q3E principles through: extractables and leachables studies under representative and stress conditions with toxicological assessment; container-closure integrity established by a validated physical method and correlated to microbial ingress; functional qualification of injection/glide force, break-loose force, needle safety, and dose delivery across the storage range and after ambient equilibration; and compatibility confirming no adverse interaction between the high-concentration bispecific formulation (including polysorbate 80) and the fluid path, silicone lubrication, or stopper coating over shelf life. Subvisible-particle and aggregation data on stored, actuated units confirm that device delivery does not compromise the product-quality profile.

3.2.P.8 Stability

Long-term storage at 2-8 C protected from light; a proposed shelf life supported by real-time, accelerated, and stress ICH Q5C/Q1A(R2) data, with defined in-use (room-temperature) and transport-excursion allowances. The stability program follows a bracketing/matrixing design across representative primary-container and device configurations and monitors the stability-indicating attributes established in development: appearance and color, protein concentration, aggregation/HMW (SE-HPLC), size heterogeneity and fragmentation (CE-SDS), charge variants (iCIEF/IEX), potency (cell-based reporter with dual-binding confirmation as warranted), subvisible and visible particulates, pH, polysorbate 80 content, and container-closure integrity.

Forced-degradation and stress studies (thermal, light per ICH Q1B, agitation/shear, and freeze-thaw) characterized the principal degradation pathways of the molecule — aggregation, hinge fragmentation, deamidation/isomerization-driven charge shifts, and methionine/tryptophan oxidation — and confirmed that the bispecific chain-pairing profile and dual potency are retained under recommended storage while degradation is detectable under stress, qualifying the methods as stability-indicating. Real-time and accelerated data at the labeled 2-8 C condition, protected from light, support the proposed shelf life, and a defined in-use period at room temperature together with qualified short-term transport/temperature excursions are supported by dedicated excursion and cumulative-stress studies. Post-approval stability commitments and ongoing lot monitoring are in place per ICH Q5C/Q1A(R2).

Governing guidelines: ICH Q5A-Q5E, Q6B, Q1A(R2), Q11, M4Q.